基于原发瘤淋巴结指标的结直肠癌肺转移根治术后临床风险评分模型
该研究回顾性纳入132例在中国医学科学院肿瘤医院接受结直肠癌肺转移根治性切除术的患者,中位随访54.2个月,5年无病生存率54.1%、5年总体生存率76.7%。多因素Cox分析确定原发瘤阴性淋巴结数<13枚、原发瘤pN+、肺转移瘤术前CEA≥10 ng/ml、肺转移瘤数目≥2个和需行肺门/纵隔淋巴结清扫为独立预后危险因素,并据此构建临床风险评分模型,评分≤2分、3~4分和≥5分三组总体生存率差异有统计学意义(P<0.001)。
要点
- 原发瘤阴性淋巴结数<13枚、pN+、肺转移瘤术前CEA≥10 ng/ml、肺转移瘤≥2个及需行肺门/纵隔淋巴结清扫是独立危险因素。
- 临床风险评分≤2分、3~4分和≥5分三组总体生存率差异有统计学意义(P<0.001)。
- 评分≥3分患者应慎重评估直接手术治疗的适宜性。
核心结论
- 原发瘤阴性淋巴结数<13枚、原发瘤pN+、肺转移瘤术前CEA≥10 ng/ml、肺转移瘤数目≥2个和需行肺门/纵隔淋巴结清扫是结直肠癌肺转移根治术后的独立危险因素。
- 依据5个独立危险因素构建的临床风险评分模型显示,评分≥3分的患者应慎重考虑直接手术治疗。
研究设计与样本
- 回顾性收集2010年1月至2020年12月在中国医学科学院肿瘤医院因结直肠癌肺转移接受根治性切除术的132例患者的临床病理资料及随访数据。
- 采用单因素和多因素Cox比例风险回归模型分析影响预后的临床病理因素,并构建风险分层模型。
主要发现
- 132例患者中位随访54.2个月,46.2%(61例)出现复发转移,5年无病生存率54.1%;25.0%(33例)死亡,5年总体生存率76.7%。
- 单因素Cox分析显示10项临床病理因素与总体生存有关(均P<0.05)。
- 多因素Cox分析显示原发瘤阴性淋巴结数<13枚(HR=3.01,95% CI:1.28~7.03,P=0.011)、原发瘤pN+(HR=5.04,95% CI:1.51~16.84,P=0.009)、肺转移瘤术前CEA≥10 ng/ml(HR=5.39,95% CI:1.80~16.19,P=0.003)、肺转移瘤数目≥2个(HR=2.47,95% CI:1.09~5.60,P=0.030)和需行肺门/纵隔淋巴结清扫(HR=2.74,95% CI:1.15~6.52,P=0.023)是独立危险因素。
- 临床风险评分≤2分、3~4分和≥5分三组患者总体生存率差异有统计学意义(P<0.001)。
关键数值与推荐
- 独立危险因素赋值依据:原发瘤阴性淋巴结数<13枚、原发瘤pN+、肺转移瘤术前CEA≥10 ng/ml、肺转移瘤数目≥2个、需行肺门/纵隔淋巴结清扫。
- 风险分层:临床风险评分≤2分、3~4分和≥5分三组总体生存率差异有统计学意义(P<0.001)。
- 评分≥3分患者应慎重考虑直接手术治疗。
临床怎么用
- 对结直肠癌肺转移拟行根治性切除术的患者,可依据原发瘤阴性淋巴结数、pN状态、肺转移瘤术前CEA、肺转移瘤数目及是否需行肺门/纵隔淋巴结清扫计算临床风险评分。
- 评分≥3分提示预后风险较高,应慎重评估直接手术治疗的适宜性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinicopathological factors affecting the prognosis of patients after curative resection of lung metastases (LMs) from colorectal cancer (CRC) and to construct a clinical risk scoring (CRS) model. Methods: This study retrospectively collected clinicopathological data and follow-up information on 132 patients who underwent radical resection of LMs from CRC at the Cancer Hospital of the Chinese Academy of Medical Sciences between January 2010 and December 2020. We analyzed the clinicopathological factors influencing patient prognosis using univariate and multivariate Cox proportional hazards regression models, and we developed a risk stratification model for prognostic prediction. Results: The median follow-up duration for the cohort of 132 patients was 54.2 months. During this period, 61 patients (46.2%) experienced recurrence or distant metastasis, resulting in a 5-year DFS rate of 54.1%. Additionally, 33 patients (25.0%) died, corresponding to a 5-year overall survival (OS) rate of 76.7%. Univariate Cox proportional hazards regression model analysis indicated that ten clinicopathological factors were significantly associated with OS (all P<0.05). These factors include the total number of lymph nodes (LNs) dissected from the primary tumor (PT) <16, the number of negative LNs from the PT <13, pN(+) of the PT, logarithmic odds of positive lymph nodes (LODDS) of the PT ≥-1.1, lymph nodes ratio (LNR) of the PT ≥0.02, preoperative carcinoembryonic antigen (CEA) level before LMs resection ≥10 ng/ml, the presence of hilar/mediastinal LN metastasis, the number of LMs ≥2, the maximum diameter of LMs ≥2.5 cm, and the necessity for hilar/mediastinal lymphadenectomy. Multivariate Cox proportional hazards regression analysis identified the number of negative LNs <13 (HR=3.01, 95% CI: 1.28-7.03, P=0.011), pN(+) of the PT (HR=5.04, 95% CI: 1.51-16.84, P=0.009), preoperative CEA level before LMs resection ≥10 ng/ml (HR=5.39, 95% CI: 1.80-16.19, P=0.003), the number of LMs ≥2 (HR=2.47, 95% CI: 1.09-5.60, P=0.030), and the necessity for hilar/mediastinal lymphadenectomy (HR=2.74, 95% CI: 1.15-6.52, P=0.023) as independent prognostic risk factors. Patients were categorized based on independent risk factors, revealing statistically significant differences in OS across the groups with CRS scores of ≤2, 3~4, and ≥5 (P<0.001). Conclusions: Independent risk factors associated with LMs from CRC patients include the number of negative LNs <13, pN(+) of the PT, preoperative CEA level before LMs resection ≥10 ng/ml, the number of LMs ≥2, and the necessity for hilar/mediastinal lymphadenectomy. Patients scoring 3 or higher on the CRS model may warrant cautious assessment for the appropriateness of direct surgical treatment. 目的: 分析结直肠癌肺转移根治性切除术后影响预后的因素并构建风险评分模型。 方法: 回顾性收集2010年1月至2020年12月在中国医学科学院肿瘤医院因结直肠癌肺转移接受根治性切除术的132例患者的临床病理资料及随访数据,通过单因素和多因素Cox比例风险回归模型分析影响患者预后的临床病理因素并构建预测预后的风险分层模型。 结果: 132例患者的中位随访时间为54.2个月。46.2%(61例)的患者出现复发转移,5年无病生存率为54.1%。25.0%(33例)的患者出现死亡事件,5年总体生存率为76.7%。单因素Cox比例风险回归模型分析显示,原发瘤淋巴结清扫总数<16枚、原发瘤阴性淋巴结数<13枚、原发瘤pN+、原发瘤阳性淋巴结对数比≥-1.1、原发瘤阳性淋巴结比率≥0.02、肺转移瘤术前癌胚抗原(CEA)水平≥10 ng/ml、存在肺门/纵隔淋巴结转移、肺转移瘤数目≥2个、肺转移瘤最大长径≥2.5 cm和需行肺门/纵隔淋巴结清扫这10项临床病理因素与患者总体生存有关(均P<0.05)。多因素Cox比例风险回归模型分析显示,原发瘤阴性淋巴结数<13枚(HR=3.01,95% CI:1.28~7.03,P=0.011)、原发瘤pN+(HR=5.04,95% CI:1.51~16.84,P=0.009)、肺转移瘤术前CEA水平≥10 ng/ml(HR=5.39,95% CI:1.80~16.19,P=0.003)、肺转移瘤数目≥2个(HR=2.47,95% CI:1.09~5.60,P=0.030)和需行肺门/纵隔淋巴结清扫(HR=2.74,95% CI:1.15~6.52,P=0.023)是影响预后的独立危险因素。依据独立危险因素将患者进行预后分层,其中临床风险评分≤2分、3~4分和≥5分的患者总体生存率差异有统计学意义(P<0.001)。 结论: 原发瘤阴性淋巴结数<13枚、原发瘤pN+、肺转移瘤术前CEA水平≥10 ng/ml、肺转移瘤数目≥2个和需行肺门/纵隔淋巴结清扫是影响结直肠癌肺转移患者术后的独立危险因素,且依据5个独立危险因素构建的临床风险评分模型提示≥3分的患者应慎重考虑直接手术治疗。.
引用
- Xiang RS, Zhang Q, Lu SB, et al. [Establishment of a clinical risk scoring model for patients undergoing curative resection of pulmonary metastases from colorectal cancer based on primary tumor lymph node indices]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 41130785. doi:10.3760/cma.j.cn112152-20250302-00081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。